BLRX
BioLineRx Breaks Ground in Glioblastoma Treatment with GLIX1
In a major breakthrough for glioblastoma treatment, BioLineRx has announced significant progress on its highly innovative molecule, GLIX1. The company's Chief Executive Officer, Phil Serlin, highlighted the advancements made during their fourth quarter and full year 2025 financial results conference call. GLIX1 is a first-in-class oral small molecule